Strong Q4 2024 Financial Performance and 2025 Outlook
February 6, 2025 - 17:33
In the fourth quarter of 2024, the company reported a remarkable 45% increase in revenue, reaching $13.53 billion. This surge was primarily fueled by significant volume growth from its flagship products, Mounjaro and Zepbound. The performance in this quarter showcases the company's robust market presence and the effectiveness of its growth strategies.
Additionally, non-incretin revenue experienced a solid 20% increase compared to the same period in 2023, reflecting the company's diverse portfolio and successful expansion into new therapeutic areas. The strong financial results indicate not only the popularity of its current offerings but also the potential for future growth.
Looking ahead, the company has provided guidance for 2025, emphasizing its commitment to innovation and market leadership. With a focus on enhancing product accessibility and exploring new opportunities, the company is well-positioned to sustain its momentum and deliver continued value to stakeholders in the coming year.
MORE NEWS
September 16, 2026 - 00:55
Warren Calls for Probe Into Crypto Firm With Trump TiesSenator Elizabeth Warren is pressing federal regulators to open an investigation into a cryptocurrency venture connected to President Donald Trump, arguing that the arrangement raises serious...
September 15, 2026 - 03:36
Veteran Debt Finance Expert Joins Foley HoagAnna Dodson has joined Foley Hoag`s Boston office, stepping into the role of co-chair of the debt finance practice. With a wealth of experience in the field, Dodson`s arrival is expected to bolster...
September 14, 2026 - 04:45
Intuit Targets New Customers, AI Growth as QuickBooks and TurboTax Bets ScaleIntuit is placing a sharper focus on bringing in first-time customers while it continues to grow its largest business lines, according to comments made by Chief Financial Officer Sandeep Singh...
September 13, 2026 - 08:33
$10,000 in Tesla When It Joined the S&P 500 Would Be About $15,700 Today. An Index Fund Would Have Done Better.When Tesla joined the S&P 500 in December 2020, index funds were forced to buy the stock at a record price of $695 a share. Investors who put $10,000 into Tesla at that moment would have roughly...